Advertisement

Topics

Grünenthal Company Profile

15:42 EDT 23rd August 2017 | BioPortfolio

Grünenthal è una società farmaceutica indipendente, basata sulla ricerca con operazioni internazionali. E' sempre stata una società a capitale privato fin dalla sua fondazione nel 1946. I prodotti Grünenthal sono commercializzati in oltre 80 Paesi e il numero delle filiali è in continua crescita. Grünenthal occupa circa 4.800 persone a livello mondiale, persone che hanno dato un grande contributo per il successo della Società.L'ulteriore consolidamento attraverso una ricerca innovativa è una parte integrante della politica della nostra Società. L'ambizione di Grünenthal è quella di essere una società leader nella Ricerca e Sviluppo in campi selezionati: l'area dolore è la nostra competenza core.

Location

Via Correggio, 43
Milano
20149
Italy

Contact

Phone: 39-02-43051
Fax: 39-02-430555
Email: dg@grunenthal.com


News Articles [29 Associated News Articles listed on BioPortfolio]

Grünenthal recruits AstraZeneca exec as CCO

German family-owned drugmaker Grünenthal has appointed Mark Fladrich to the position of chief commercial…

Grünenthal buys right to migraine drug in up to $300 million deal

Anglo-Swedish pharma major AstraZeneca has entered an agreement with family-owned German drugmaker Grünenthal…

Grünenthal opens Innovation Hub in Boston

Grünenthal, the German family-owned leader in pain, says that it has opened a new Innovation Hub in…

AZ divests migraine drug to Grünenthal

AstraZeneca has sold global rights (ex Japan) for its migraine drug Zomig to Grünenthal, as it continues to shed products outside of its area of strategic focus.

Grünenthal schließt Vereinbarung mit AstraZeneca zum Erwerb der globalen Rechte an dem Migränemedikament Zomig® (Zolmitriptan)

Aachen (ots) - - Diese Akquisition stärkt Grünenthals führende Position im Bereich der Schmerzbehandlung - Grünenthal erweitert damit sein Schmerzportfolio um ein Medikament zur Behandlung von Mig...

Astrazeneca To Divest Rights To Migraine Drug Zomig To Grünenthal

LONDON (dpa-AFX) - AstraZeneca plc. (AZN.L, AZN) Wednesday announced that it has entered an agreement with Grünenthal, a German family-owned pharma company, for the global rights to Zomig (zolmitr...

AstraZeneca to sell global rights for migraine treatment Zomig to Grünenthal

UK-based AstraZeneca has entered an agreement with German pharmaceutical company Grünenthal to divest the global rights to Zomig (zolmitriptan) outside Japan.

Mark Fladrich appointed new CCO at Grünenthal

The Grünenthal Group announced that Mark Fladrich will take over the position as Chief Commercial Officer (CCO) responsible for the entire Global Commercial Organization. Currently Mark Fladrich is A...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [4 Associated Companies listed on BioPortfolio]

Grünenthal Group

The Grünenthal Group is an independent, family-owned company, headquartered in Aachen, Germany. It is present in 32 countries with affiliates in Europe, Latin America and the U...

Grünenthal

Grünenthal è una società farmaceutica indipendente, basata sulla ricerca con operazioni internazionali. E' sempre stata una società a capitale privato fin dalla sua fondazione nel 1946. I prodotti...

Gr?nenthal

Grünenthal GmbH

Nil

More Information about "Grünenthal" on BioPortfolio

We have published hundreds of Grünenthal news stories on BioPortfolio along with dozens of Grünenthal Clinical Trials and PubMed Articles about Grünenthal for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Grünenthal Companies in our database. You can also find out about relevant Grünenthal Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record